Clinical nutrition (Edinburgh, Scotland) · 2025
The effect of enteral glycine on plasma glycine and muscle structure, size, and function in the critically ill: A randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ali Abdelhamid Yasmine, Bongetti Amy J, Caldow Marissa K, Karahalios Amalia, Wittholz Kym, Fetterplace Kate, Beach Lisa J, Haines Kimberley J, Tascone Brianna, De Souza David P, Elahee Doomun Sheik Nadeem, Presneill Jeff, Rooyackers Olav, Koopman Rene, Lynch Gordon S, Deane Adam M
Аннотация
BACKGROUND: Critically ill patients frequently experience severe muscle loss with subsequent physical impairment. In pre-clinical models of muscle wasting, administration of the amino acid glycine attenuates muscle loss.
AIMS: To evaluate the plasma availability of enteral glycine and the impact of glycine supplementation on muscle loss in critical illness.
METHODS: Parallel group, blinded, randomized clinical trial. Mechanically ventilated patients were randomized to receive low- or high-dose glycine (0.2 or 0.4 g/kg/day) or placebo, in addition to usual care, for a maximum of 7 days. On day 1, plasma samples were obtained at regular intervals for 240 min to measure glycine concentrations. Quadriceps muscle thickness was measured with ultrasound at baseline, days 3 and 7. Needle biopsies of the vastus lateralis muscle were obtained at baseline and end of intervention. The primary outcome was plasma glycine availability (plasma glycine area under curve over 240 min, AUC240). Secondary outcomes included muscle glycine concentration, myofiber diameter, quadriceps muscle thickness, physical function and length of stay.
RESULTS: Twenty-nine patients were randomized (placebo n = 10, low-dose glycine n = 9, high-dose glycine n = 10). Patients received a median (interquartile range) of 16.2 (4.6-16.4) g and 29.6 (24.8-32.4) g glycine per day in the low- and high-dose intervention groups. There was a dose-dependent increase in plasma glycine availability (Mean difference AUC240 high-dose glycine vs placebo: 759.40 μmol/L.min; 95 % CI 219.27, 1299.54, p = 0.008) and muscle glycine concentration (Mean difference high-dose glycine vs placebo: 0.16 nmol/mg muscle wet mass; 95 % CI 0.08, 0.23, p = 0.001). Point estimates favoured attenuated loss of quadriceps muscle thickness in patients receiving high-dose glycine (Mean difference high-dose glycine vs placebo: 0.11 cm; 95 % CI: -0.10, 0.31, p = 0.299). However, glycine supplementation had no effect on myofiber diameter. Patients who received glycine had shorter ICU and hospital admissions.
CONCLUSION: In critically ill patients, glycine supplementation increases plasma and muscle glycine concentrations and the effect of glycine on muscle loss warrants further evaluation in larger studies.
TRIAL REGISTRATION: This trial was prospectively registered with the Australian and New Zealand Clinical Trials Registry (www.anzctr.org.au) ANZCTR ACTRN12618000409279.
AIMS: To evaluate the plasma availability of enteral glycine and the impact of glycine supplementation on muscle loss in critical illness.
METHODS: Parallel group, blinded, randomized clinical trial. Mechanically ventilated patients were randomized to receive low- or high-dose glycine (0.2 or 0.4 g/kg/day) or placebo, in addition to usual care, for a maximum of 7 days. On day 1, plasma samples were obtained at regular intervals for 240 min to measure glycine concentrations. Quadriceps muscle thickness was measured with ultrasound at baseline, days 3 and 7. Needle biopsies of the vastus lateralis muscle were obtained at baseline and end of intervention. The primary outcome was plasma glycine availability (plasma glycine area under curve over 240 min, AUC240). Secondary outcomes included muscle glycine concentration, myofiber diameter, quadriceps muscle thickness, physical function and length of stay.
RESULTS: Twenty-nine patients were randomized (placebo n = 10, low-dose glycine n = 9, high-dose glycine n = 10). Patients received a median (interquartile range) of 16.2 (4.6-16.4) g and 29.6 (24.8-32.4) g glycine per day in the low- and high-dose intervention groups. There was a dose-dependent increase in plasma glycine availability (Mean difference AUC240 high-dose glycine vs placebo: 759.40 μmol/L.min; 95 % CI 219.27, 1299.54, p = 0.008) and muscle glycine concentration (Mean difference high-dose glycine vs placebo: 0.16 nmol/mg muscle wet mass; 95 % CI 0.08, 0.23, p = 0.001). Point estimates favoured attenuated loss of quadriceps muscle thickness in patients receiving high-dose glycine (Mean difference high-dose glycine vs placebo: 0.11 cm; 95 % CI: -0.10, 0.31, p = 0.299). However, glycine supplementation had no effect on myofiber diameter. Patients who received glycine had shorter ICU and hospital admissions.
CONCLUSION: In critically ill patients, glycine supplementation increases plasma and muscle glycine concentrations and the effect of glycine on muscle loss warrants further evaluation in larger studies.
TRIAL REGISTRATION: This trial was prospectively registered with the Australian and New Zealand Clinical Trials Registry (www.anzctr.org.au) ANZCTR ACTRN12618000409279.